NDC product
Robitussin Maximum Strength Severe Multi-Symptom Cough Cold Flu Nighttime
NDC 0031-0101 · Haleon US Holdings LLC
Key facts
| Product NDC | 0031-0101 |
|---|---|
| Proprietary name | Robitussin Maximum Strength Severe Multi-Symptom Cough Cold Flu Nighttime |
| Nonproprietary name | acetaminophen, diphenhydramine hcl |
| Substances | ACETAMINOPHEN, DIPHENHYDRAMINE HYDROCHLORIDE |
| Dosage form | LIQUID |
| Route | ORAL |
| Labeler | Haleon US Holdings LLC |
| Product type | HUMAN OTC DRUG |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M012 |
| Pharmacologic classes | Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC] |
| Marketing start | Feb 15, 2024 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: